Giant Biogene Holding Co., Ltd.

SEHK:2367 Stock Report

Market Cap: HK$52.4b

Giant Biogene Holding Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Jianya Yan

Chief executive officer

CN¥11.9m

Total compensation

CEO salary percentage5.1%
CEO tenure2.7yrs
CEO ownership0.09%
Management average tenureno data
Board average tenure2.2yrs

Recent management updates

Recent updates

Giant Biogene Holding Co., Ltd. (HKG:2367) Shares Could Be 50% Below Their Intrinsic Value Estimate

Nov 20
Giant Biogene Holding Co., Ltd. (HKG:2367) Shares Could Be 50% Below Their Intrinsic Value Estimate

Revenue Beat: Giant Biogene Holding Co., Ltd. Beat Analyst Estimates By 12%

Aug 21
Revenue Beat: Giant Biogene Holding Co., Ltd. Beat Analyst Estimates By 12%

Does Giant Biogene Holding (HKG:2367) Deserve A Spot On Your Watchlist?

Aug 09
Does Giant Biogene Holding (HKG:2367) Deserve A Spot On Your Watchlist?

Giant Biogene Holding Co., Ltd.'s (HKG:2367) Popularity With Investors Is Clear

Jul 01
Giant Biogene Holding Co., Ltd.'s (HKG:2367) Popularity With Investors Is Clear

Is Giant Biogene Holding Co., Ltd. (HKG:2367) Trading At A 32% Discount?

Apr 17
Is Giant Biogene Holding Co., Ltd. (HKG:2367) Trading At A 32% Discount?

Investors Interested In Giant Biogene Holding Co., Ltd.'s (HKG:2367) Earnings

Mar 28
Investors Interested In Giant Biogene Holding Co., Ltd.'s (HKG:2367) Earnings

Giant Biogene Holding Co., Ltd. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

Mar 27
Giant Biogene Holding Co., Ltd. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

Do Giant Biogene Holding's (HKG:2367) Earnings Warrant Your Attention?

Dec 24
Do Giant Biogene Holding's (HKG:2367) Earnings Warrant Your Attention?

CEO Compensation Analysis

How has Jianya Yan's remuneration changed compared to Giant Biogene Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

CN¥2b

Mar 31 2024n/an/a

CN¥2b

Dec 31 2023CN¥12mCN¥606k

CN¥1b

Sep 30 2023n/an/a

CN¥1b

Jun 30 2023n/an/a

CN¥1b

Mar 31 2023n/an/a

CN¥874m

Dec 31 2022CN¥10mCN¥600k

CN¥696m

Dec 31 2021CN¥10mCN¥600k

CN¥809m

Compensation vs Market: Jianya's total compensation ($USD1.63M) is above average for companies of similar size in the Hong Kong market ($USD789.70K).

Compensation vs Earnings: Jianya's compensation has been consistent with company performance over the past year.

CEO

Jianya Yan (58 yo)

2.7yrs

Tenure

CN¥11,885,000

Compensation

Mr. Jianya Yan is Co-Founder of Giant Biogene Holding Co., Ltd., serves as its Chief Executive Officer, Executive Director & Chairman of the Board since April 21, 2022 and served as its Director since Nove...

Board Members

NamePositionTenureCompensationOwnership
Jianya Yan
CEO & Executive Chairman of the Board3.1yrsCN¥11.89m0.089%
HK$ 46.8m
Huijuan Zhang
CFO & Executive Director1.2yrsCN¥241.00kno data
Juan Ye
Senior VP & Executive Director3.1yrsCN¥1.82mno data
Juan Fang
Senior VP & Executive Director3.1yrsCN¥2.11mno data
Yubo Yan
Chief Product Officer1.2yrsCN¥140.00kno data
Sze Wing Wong
Independent Non-Executive Director2.2yrsCN¥180.00kno data
Wenhua Shan
Independent Non-Executive Director2.2yrsCN¥108.00kno data
Jin Huang
Independent Non-Executive Director2.2yrsCN¥108.00kno data

2.2yrs

Average Tenure

51yo

Average Age

Experienced Board: 2367's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 03:55
End of Day Share Price 2024/12/18 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Giant Biogene Holding Co., Ltd. is covered by 28 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Junhao FanChina International Capital Corporation Limited
Zhuonan XuChina International Capital Corporation Limited
Joseph WongChina Merchants Securities (HK) Co., Ltd